Guardant Health, Inc.: Revolutionizing Patient Care with Precision Oncology and FDA Review of ShieldTM Blood Test for Colorectal Cancer Detection

Guardant Health, Inc. (Nasdaq: GH) is a leading precision oncology company that recently had its stock trading temporarily halted by Nasdaq. The U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee’s Molecular and Clinical Genetics Panel is set to meet today to review Guardant Health’s premarket approval (PMA) application for ShieldTM, a blood test designed to screen for colorectal cancer in average-risk adults. The panel meeting is scheduled to begin at 9:30 a.m. ET.

Guardant Health, founded in 2012, is dedicated to revolutionizing patient care by providing critical insights into disease mechanisms through its advanced blood and tissue tests, real-world data, and AI analytics. The company’s tests play a vital role in improving outcomes throughout all stages of care, from early cancer detection to recurrence monitoring in early-stage cancer and assisting doctors in choosing the most suitable treatment for patients with advanced cancer.

For more information about Guardant Health, visit their website at guardanthealth.com or follow the company on LinkedIn, Twitter or Facebook for updates and news. Investors can reach out to Zarak Khurshid at investors@guardanthealth.com while media inquiries can be directed to Mike Weist at press@guardanthealth.com or by calling +1 650-647-3643.

Founded in 2012, Guardant Health is committed to transforming patient care through cutting-edge blood and tissue tests, real-world data analysis, and artificial intelligence (AI) analytics. The company’s tests are used throughout all stages of cancer care – from early detection to monitoring recurrences in early-stage cancer and helping doctors choose the best treatment options for patients with advanced cancer.

The U.S Food and Drug Administration (FDA) Medical Devices Advisory Committee’s Molecular and Clinical Genetics Panel will meet today to review Guardant Health’s premarket approval application for ShieldTM – a blood test designed to detect colorectal cancer in average-risk adults.

For more information about Guardant Health visit their website at guardanthealth.com or follow them on LinkedIn, Twitter or Facebook for updates and news.

Investors can reach out to Zarak Khurshid at investors@guardanthealth.com while media inquiries can be directed to Mike Weist at press@guardanthealth